Ophthalmology and Therapy最新文献

{"title":"Comparative Clinical Outcomes of a 1.0% Versus 1.4% Sodium Hyaluronate OVD in Cataract Surgery: A Prospective Study.","authors":"Shreyas Ramamurthy, Dandapani Ramamurthy, Bhavnita Soni, Bhargav Joshi","doi":"10.1007/s40123-026-01456-4","DOIUrl":"10.1007/s40123-026-01456-4","url":null,"abstract":"<p><strong>Introduction: </strong>Maintaining anterior chamber space and protecting the endothelial layer during surgery is the primary role of ophthalmic viscosurgical devices (OVD), which have made them an integral part of the surgery for decades now. This study evaluated sodium hyaluronate-based OVDs BIO-HYALUR (1%) and Protectalon 1.4% in terms of their performance and safety during cataract surgery.</p><p><strong>Methods: </strong>This was a prospective, comparative, randomized clinical study involving patients undergoing cataract surgery. The primary endpoint was the incidence of intraocular pressure (IOP) rise > 30 mmHg; other clinical parameters including visual acuity, endothelial cell density (ECD) and morphology, corneal thickness, intraocular inflammation, and intraoperative parameters (phacoemulsification metrics, space maintenance, and surgeon performance rating) were also compared. Postoperative evaluations were conducted at 8 ± 2 h, 24 ± 4 h, 7 ± 2 days, 30 ± 7 days, and 90 ± 14 days.</p><p><strong>Results: </strong>The study included 140 patients (70 in each group) with a mean age of 63.8 ± 7.09 years and 63.4 ± 8.81 years for the BIO-HYALUR group and the Protectalon group, respectively. No patient in either of the groups showed an incident of IOP > 30 mmHg during the study period. ECD showed no clinically meaningful loss postoperatively in either of the groups. Intraocular inflammation was completely resolved by 7 ± 2 days, and lens and corneal clarity was achieved by 24 ± 4 h in both groups. No statistically significant difference was observed between the two groups for visual acuity and corneal thickness. Full chambered space maintenance was achieved in all cases (100%). Ease of use was rated as \"excellent\" in the vast majority of cases in both groups. No adverse events or intraoperative complications were observed during the study.</p><p><strong>Conclusion: </strong>BIO-HYALUR and Protectalon 1.4% are safe and reliable OVDs in terms of intra- and postoperative parameters, and both OVDs are suitable for cataract surgery.</p><p><strong>Trial registration: </strong>CTRI/2023/03/050365.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3041-3054"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual Outcomes and Patient-Reported Dysphotopsia After PanOptix and PanOptix Toric Implantation Stratified by Preoperative Chord Mu: A Prospective Observational Cohort Study.","authors":"Xia Zhang, Lu Sun, Yongxiang Tang, Wenda Sui, Lulu Chen, Ying Xie, Ailing Bian, Yong Zhong, Zaowen Wang, Shunhua Zhang","doi":"10.1007/s40123-026-01438-6","DOIUrl":"10.1007/s40123-026-01438-6","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to evaluate the tolerance of preoperative chord mu (angle kappa) after cataract or clear lens exchange surgery and implantation of AcrySof IQ PanOptix and PanOptix Toric in a Chinese cohort.</p><p><strong>Methods: </strong>This prospective observational study consecutively enrolled patients undergoing PanOptix/PanOptix Toric implantation at Peking Union Medical College Hospital. Eyes were analyzed by chord mu (< 0.3 mm vs. ≥ 0.3 mm), lens opacity (clear lens or cataract), and intraocular lens (PanOptix or PanOptix Toric). Visual acuity was assessed at 1 and 3 months. Patient-reported outcomes were assessed at 3 months using the IOLSAT and the QUVID.</p><p><strong>Results: </strong>A total of 122 eyes from 62 patients were analyzed. Seventy-nine eyes received PanOptix Toric lenses, and 43 eyes received non-toric PanOptix lenses. The κ ≥ 0.3 mm group had less myopic spherical equivalent (P = 0.004) than the κ < 0.3 mm group. At 1 and 3 months, the uncorrected and corrected distance, intermediate, and near visual acuity outcomes were excellent and did not differ significantly between κ groups in the overall cohort (all P > 0.05). In the toric subgroup,1-m UNVA was better in eyes with κ < 0.3 mm (P < 0.001, adj. P = 0.024) than in those with κ ≥ 0.3 mm. Overall spectacle independence was 90% (45/50), with 100% for distance and intermediate vision in both κ groups; near spectacle independence was similar between groups (P = 0.797). The most frequent visual disturbances were halos (78%, 39/50), starbursts (60%, 30/50), and glare (42%, 21/50), with no significant differences between the κ groups (all P > 0.05). Patient-reported outcomes and disturbance frequencies were similar between PanOptix and PanOptix Toric (all P > 0.05). Compared with cataract surgery, clear lens exchange resulted in increased rates of halos (92.3% vs. 62.5%, P = 0.016).</p><p><strong>Conclusions: </strong>In this carefully selected, small sample Chinese cohort implanted with PanOptix/PanOptix Toric lense and restricted to eyes with chord mu ≤ 0.5 mm, a κ ≥ 0.3 mm was not associated with worse overall visual acuity, spectacle independence, or the likelihood/severity of visual disturbances. The PanOptix Toric lens demonstrated patient-reported outcomes comparable to those of the non-toric PanOptix. Patients who underwent clear lens exchange reported more visual disturbances than those who underwent cataract surgery, suggesting a need for careful candidate selection and preoperative counseling.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3117-3135"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Effect of Intravitreal Faricimab on Hard Exudates in Diabetic Macular Oedema.","authors":"Ameeta Kumar, Busaraben Gandhi, Arevik Ghulakhszian, Giovanni Ometto, Christiana Dinah","doi":"10.1007/s40123-026-01464-4","DOIUrl":"10.1007/s40123-026-01464-4","url":null,"abstract":"<p><strong>Introduction: </strong>Intravitreal faricimab is the first bispecific antibody to target vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). In the study reported here, we examined the early effect of intravitreal faricimab on hard exudates (HEs) in patients with diabetic macular oedema (DMO).</p><p><strong>Methods: </strong>Consecutive patients who were initiated on faricimab for centre-involving DMO associated with HEs between August 2022 and July 2023 were reviewed. Areas of HE were confirmed on colour fundus photographs taken at initiation of therapy and at the 6-month follow-up. ImageJ software was used for semi-automated segmentation and measurement of the HE area within the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. Demographic data, including age, gender and ethnicity, as well as best-corrected visual acuity (BCVA), central retinal thickness (CRT) and macular volume (MV) were recorded.</p><p><strong>Results: </strong>A total of 19 eyes from 16 patients were included in the study. Mean age of the cohort was 60.6 (range 49-71) years; ten eyes (53%) were treatment naïve. The median total HE area was reduced from 0.15 (interquartile range [IQR] 0.04-0.30) mm² to 0.10 (IQR 0.07-0.24) mm² by the 6-month follow-up. A greater reduction in total HE area was observed in treatment-naïve eyes (- 0.14 mm²) compared with previously treated eyes (+ 0.05 mm²), despite the former having a higher median baseline value (0.25 [IQR 0.15-0.47] mm² vs 0.05 [IQR 0.04-0.15] mm²). Mean BCVA improved from LogMAR 0.26 ± 0.22 to 0.18 ± 0.19 (p < 0.05), while mean CRT and MV reduced from 413 ± 108 to 340 ± 95 μm (p < 0.001) and from 10.03 ± 1.41 to 9.20 ± 1.17 mm³ (p < 0.0001), respectively.</p><p><strong>Conclusion: </strong>Intravitreal faricimab may be associated with reduction of HE area in DMO within 6 months of initiation, with greater effects in treatment-naïve eyes. Further studies with longer follow-up are warranted to determine the durability of HE resolution and its comparison to intravitreal steroids and other anti-VEGF agents.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3145-3156"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zero-Programmed-Sphere Keratorefractive Lenticule Extraction: Visual, Refractive, Anterior-Keratometric, and Wavefront Outcomes in a Single-Center Series of 74 Eyes.","authors":"Ivan Gabrić, Filip Grulović, Karla Bodakoš, Maja Bohač","doi":"10.1007/s40123-026-01447-5","DOIUrl":"10.1007/s40123-026-01447-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Zero-programmed-sphere keratorefractive lenticule extraction (KLEx), also called cylinder-only KLEx, is an uncommon cylinder-dominated treatment pattern in which the planned spherical correction is 0.00 diopters (D). To our knowledge, no published outcome data characterize this pattern. To address this lack of data, we retrospectively identified all such cases from a prospectively maintained single-center refractive-surgery registry and reported visual, refractive, anterior-keratometric, and wavefront outcomes, using Alpins vector analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study is retrospective single-center, single-surgeon case series of consecutive eyes treated with the SCHWIND ATOS femtosecond laser (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany) between August 2024 and March 2026 at a programmed sphere of 0.00 D. Cycloplegic refraction was 0.00 D sphere in all 74 eyes (cycloplegic-plano target). The data lock was 31 March 2026, and eyes treated within the 3 months preceding that date were classified as not yet eligible to be included in the study. Inter-eye dependence was assessed using generalized estimating equations (GEE), and refractive stability was studied using a linear mixed model. Corrected distance visual acuity (CDVA) was imputed as uncorrected distance visual acuity (UDVA) when UDVA ≥ 20/20 and CDVA was missing. Complete-case sensitivity was also reported. The full-cohort ideal-outcome convention was determined using the refractive Alpins metric with a nonzero-difference-vector (DV) sensitivity subgroup; a parallel anterior-keratometric Alpins was run on the paired-keratometry subset.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 74 eyes had been treated with the SCHWIND ATOS platform. At data lock, 62 were eligible for the ≥ 3-month follow-up and 37 had completed refractive examinations (analyzed primary cohort; mean age 33 years; mean programmed cylinder - 2.96 ± 1.30 D). UDVA ≥ 20/20 and ≥ 20/25 was achieved in 75.7% (Wilson 59.9-86.6%) and 91.9% of eyes, respectively; 83.8% of eyes were within ± 0.50 D of plano spherical equivalent refraction (SEQ); and 73.0% of eyes had postoperative cylinder ≤ 0.50 D. In terms of the refractive Alpins (side-by-side), the full-cohort correction index (CI) was 1.04, and mean absolute angle of error (|AoE|) was 2.9° versus 5.2° in the nonzero-DV subgroup (n = 21). In the 25-eye paired-keratometry subset, anterior-keratometric Alpins gave a CI of 1.05 and |AoE| of 13.4°, with residual anterior-keratometric DV of 1.12 ± 0.45 D versus refractive DV of 0.44 ± 0.60 D. Among the nine eyes with UDVA &lt; 20/20, four had directly measured postoperative CDVA and five were not eligible for the imputation rule; the paired safety analysis therefore included 32 eyes (28 imputed + 4 directly measured), with complete-case (n = 4) and imputation-based indices 0.98 and 1.25, respectively. The analyzed cohort overrepresented against-the-rule (ATR) and oblique astigmatism","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2919-2936"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-Head Comparison of an IGF-1R Inhibitor Versus Intravenous Glucocorticoid for Active Thyroid Eye Disease: Design of a Randomized Clinical Trial.","authors":"Haiyang Zhang, Jing Sun, Yinwei Li, Yazhuo Huang, Shuo Zhang, Sisi Zhong, Junjie Deng, Bingxue Zhu, Shujie Lu, Wen Zhang, Han Han-Zhang, Yulia Jin, Lei Qian, Huifang Zhou, Xianqun Fan","doi":"10.1007/s40123-026-01451-9","DOIUrl":"10.1007/s40123-026-01451-9","url":null,"abstract":"<p><strong>Introduction: </strong>Thyroid eye disease (TED) is a disfiguring and potentially sight-threatening autoimmune orbital disorder. Intravenous glucocorticoid (IVGC) is the current first-line treatment for active, moderate-to-severe TED but its efficacy in reducing proptosis and diplopia is limited and inconsistent, with high relapse rates. In recent years, inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) have emerged as a novel therapeutic class for TED. Clinical studies have demonstrated that IGF-1R inhibitors can significantly reduce proptosis and improve overall disease activity in patients with active, moderate-to-severe TED. Although both therapies are available, no head-to-head clinical trial has directly compared IGF-1R inhibitors with IVGC. Therefore, this study aims to evaluate the efficacy and safety of an IGF-1R inhibitor compared with IVGC pulse therapy on proptosis in patients with active TED.</p><p><strong>Methods: </strong>This is a multicenter, randomized, open-label, active-controlled phase 4 trial. Adults with active moderate-to-severe TED and baseline proptosis ≥ 16 mm in the study eye will be enrolled. Participants will be randomized 1:1 to receive either intravenous teprotumumab N01 (10 mg/kg initial dose on day 1, followed by 20 mg/kg at weeks 3, 6, 9, and 12) or IVGC pulse therapy (methylprednisolone 500 mg on day 1 and from week 1 to week 5, followed by 250 mg from week 6 to week 11). After completing the 12-week treatment period, participants will enter an extended treatment and observation phase. The primary outcome measure is the proportion of participants who achieve a ≥ 2-mm reduction in proptosis in the study eye at week 15. Key secondary outcome measures include the change from baseline in proptosis and the overall responder rate in the study eye at week 15.</p><p><strong>Planned outcomes: </strong>This study plans to enroll approximately 92 participants with active TED. This trial is the first head-to-head clinical study comparing an IGF-1R (Insulin-like growth factor-1 receptor) inhibitor with IVGC. It aims to address the limitations of IVGC, including its uncertain efficacy on proptosis and diplopia, by utilizing a targeted approach to provide more comprehensive clinical evidence for TED treatment.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT07265258 (RESTORE-4).</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3157-3171"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148448531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement in Visual-Tasking Daily Living Activities and Work Productivity in Patients with Dry Eye Disease: Integrated Analysis of COMET Studies.","authors":"Laura M Periman, Cory J Lappin, Marguerite B McDonald, Jade Coats, Guruprasad R Pattar, Tony Okoro, Nathan Lighthizer, Michelle Senchyna, Lisa M Nijm","doi":"10.1007/s40123-026-01421-1","DOIUrl":"10.1007/s40123-026-01421-1","url":null,"abstract":"<p><strong>Introduction: </strong>Dry eye disease (DED) symptoms can impair activities of daily living (ADLs) and work productivity (WP). This post hoc integrated analysis of the phase 2b COMET-1 (NCT04498182) and phase 3 COMET-2 (NCT05285644) and COMET-3 (NCT05360966) studies explored the effectiveness of acoltremon ophthalmic solution 0.003% (ACO [Tryptyr^®]), a recently approved treatment for DED signs and symptoms, on visual-tasking ADLs and WP.</p><p><strong>Methods: </strong>These randomized, double-masked, vehicle (VEH)-controlled studies had similar designs and identical eligibility criteria, enrolling adults aged ≥ 30 years with prespecified DED signs and symptoms. Patients were randomized 1:1 to receive ACO or VEH in both eyes twice daily for 84 (COMET-1) or 90 (COMET-2 and COMET-3) days. The degree that DED symptoms interfered with visual-tasking ADLs and WP was assessed on visual analog scales (VAS; 0-100 mm). ADL/WP and Symptom Assessment iN Dry Eye (SANDE) questionnaires and safety assessments were collected on days 1, 14, 28, and 84/90. Least-squares (LS) mean change from baseline (CFB) and responder analyses were analyzed using analysis of covariance and Cochran-Mantel-Haenszel test, respectively.</p><p><strong>Results: </strong>Positive treatment effects in favor of ACO (n = 584) versus VEH (n = 595) were observed for LS mean difference in CFB from days 14 through 84/90 in the ability to use electronic devices (day 14, - 4.4 [P = 0.0016]; day 28, - 5.4 [P = 0.0002]; day 84/90, - 3.4 [P = 0.0378]), a visual-tasking composite score (day 14, - 3.7 [P = 0.0023]; day 28, - 4.2 [P = 0.0012]; day 84/90, - 3.1 [P = 0.0307]), and WP (day 14, - 4.4 [P = 0.0104]; day 28, - 5.4 [P = 0.0028]; day 84/90, - 4.4 [P = 0.0229]). Responder analyses favoring ACO supported the meaningfulness of observed CFB reductions. The only ocular treatment-emergent adverse event with > 1.5% incidence was instillation-site burning or stinging (ACO, 50.2% [97.6% mild]; VEH, 3.2% [100% mild]).</p><p><strong>Conclusions: </strong>These exploratory data suggest that ACO is associated with rapid and sustained improvements in visual-tasking ADLs and WP.</p><p><strong>Trial registration: </strong>COMET-1, NCT04498182; COMET-2, NCT05285644; COMET-3, NCT05360966.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3025-3039"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study.","authors":"Dun Jack Fu, Eleonora Riotto, Luke Nicholson, Sandro Fasolo, Omer Trivizki, Kimberly Spooner, Sobha Sivaprasad, Livia Faes","doi":"10.1007/s40123-026-01457-3","DOIUrl":"10.1007/s40123-026-01457-3","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate 12-month real-world outcomes of faricimab for polypoidal choroidal vasculopathy (PCV) in a multi-ethnic cohort.</p><p><strong>Methods: </strong>This was a single-center retrospective cohort study of consecutive eyes with PCV diagnosed in routine care, treated with intravitreal faricimab, and with complete baseline and 12-month follow-up. One eye per patient was analyzed. Outcomes were reported for treatment-naïve and treatment-experienced eyes switched for persistent activity or limited durability. Primary endpoints were change in visual acuity (VA) and central subfield thickness (CST) at 12 months. Ethnicity-stratified outcomes were assessed secondarily.</p><p><strong>Results: </strong>The cohort comprised 159 eyes (40 treatment-naïve, 119 treatment-experienced). In treatment-naïve eyes, mean VA improved from 61 (standard deviation [SD] 14) letters at baseline by + 6.8 letters (SD 16; P < 0.01) at 12 months, with CST reduction of - 54 µm (SD 100; P < 0.01) and mean 9.6 (SD 4.2) injections. In treatment-experienced eyes, paired VA change at 12 months was minimal (+ 0.27 letters, SD 12; P > 0.05), while CST decreased significantly by - 40 µm (SD 110; P < 0.01). Eyes received a mean of 8.2 (SD 4.2) faricimab injections over 12 months. Exploratory ethnicity-stratified analyses demonstrated baseline heterogeneity across groups, with broadly favorable anatomical and functional outcomes observed across the multi-ethnic cohort, but subgroup sizes precluded comparative efficacy assessment.</p><p><strong>Conclusions: </strong>In routine care, faricimab was associated with clinically meaningful visual improvement in treatment-naïve PCV and anatomical improvement in both treatment-naïve and -experienced eyes. Prospective studies with adequate ethnic representation are needed to validate these findings.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3071-3088"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148592927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding \"Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials\".","authors":"Georgios D Panos","doi":"10.1007/s40123-026-01440-y","DOIUrl":"10.1007/s40123-026-01440-y","url":null,"abstract":"","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3173-3175"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148423082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macular Pigment Changes in Patients with Diabetes Mellitus and Without Diabetic Retinopathy.","authors":"Alessandro Arrigo, Emanuela Aragona, Gianpaolo Zerbini, Pasquale Aragona, Francesco Bandello","doi":"10.1007/s40123-026-01458-2","DOIUrl":"10.1007/s40123-026-01458-2","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic retinopathy (DR) is a common complication of diabetes mellitus (DM) and a leading cause of vision impairment in developed countries. Macular pigment optical density (MPOD) assessment provides a non-invasive method for evaluating in vivo changes in macular pigment. In this study, we investigated macular pigment alterations in eyes of patients with type 2 DM without clinically detectable DR using an autofluorescence-based MPOD (AF-MPOD) technique.</p><p><strong>Methods: </strong>This was an observational, cross-sectional study including patients with type 2 DM without signs of DR and age- and gender-matched healthy controls. Confocal autofluorescence-based MPOD imaging was used to quantify macular pigment changes within the central 6.0° eccentricity. Retinal structural and microvascular alterations were also assessed using optical coherence tomography (OCT) and OCT angiography (OCTA). The primary outcome measure was the quantitative assessment of AF-MPOD parameters. Secondary outcomes included the evaluation of OCT and OCTA alterations and the exploratory identification of distinct imaging phenotypes among diabetic patients.</p><p><strong>Results: </strong>Forty eyes from patients with type 2 DM and 40 control eyes were included. Eyes from patients with DM showed significantly reduced AF-MPOD parameters and lower OCTA vessel density compared with healthy control eyes (all adjusted p < 0.001). Inner retinal thinning was also observed. Glycemic control was inversely associated with AF-MPOD values and vessel density, whereas higher body mass index showed strong associations with AF-MPOD reduction. AF-MPOD parameters remained independently associated with OCTA-derived vascular metrics after multivariable adjustment.</p><p><strong>Conclusions: </strong>Our findings suggest that an early, interconnected neurovascular-metabolic retinal dysfunction may be detectable before the onset of clinically visible DR. AF-MPOD assessment may provide complementary imaging information on early retinal involvement in DM and warrants further validation in longitudinal studies.</p><p><strong>Clinical trial registration: </strong>Protocol ID: PNRR-MAD-2022-12376008; ClinicalTrials.gov Identifier: NCT06582472.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3101-3115"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to: Letter to the Editor Regarding \"Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials\".","authors":"Scott M Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping, Keith Chan, Theodore Leng, Nimesh Patel","doi":"10.1007/s40123-026-01439-5","DOIUrl":"10.1007/s40123-026-01439-5","url":null,"abstract":"","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3177-3180"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148423011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}